- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- GLENMARK PHARMA - ABBOTT INDIA
GLENMARK PHARMA vs ABBOTT INDIA - Comparison Results
GLENMARK PHARMA 
Change
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
ABBOTT INDIA
Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
Current Valuations
| GLENMARK PHARMA | ABBOTT INDIA | GLENMARK PHARMA/ ABBOTT INDIA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 22.5 | 40.4 | 55.7% | View Chart |
| P/BV | x | 3.5 | 9.6 | 36.8% | View Chart |
| Dividend Yield | % | 0.3 | 0.7 | 47.6% |
Financials
 GLENMARK PHARMA  ABBOTT INDIA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| GLENMARK PHARMA Mar-17 |
ABBOTT INDIA Mar-18 |
GLENMARK PHARMA/ ABBOTT INDIA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 993 | 6,110 | 16.3% | |
| Low | Rs | 729 | 3,996 | 18.3% | |
| Sales per share (Unadj.) | Rs | 325.5 | 1,552.2 | 21.0% | |
| Earnings per share (Unadj.) | Rs | 39.3 | 188.8 | 20.8% | |
| Cash flow per share (Unadj.) | Rs | 48.7 | 196.4 | 24.8% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 55.00 | 3.6% | |
| Dividend yield (eoy) | % | 0.2 | 1.1 | 21.3% | |
| Book value per share (Unadj.) | Rs | 159.2 | 796.6 | 20.0% | |
| Shares outstanding (eoy) | m | 282.17 | 21.25 | 1,327.9% | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 2.6 | 3.3 | 81.3% | |
| Avg P/E ratio | x | 21.9 | 26.8 | 81.9% | |
| P/CF ratio (eoy) | x | 17.7 | 25.7 | 68.8% | |
| Price / Book Value ratio | x | 5.4 | 6.3 | 85.3% | |
| Dividend payout | % | 5.1 | 29.1 | 17.5% | |
| Avg Mkt Cap | Rs m | 242,991 | 107,376 | 226.3% | |
| No. of employees | `000 | 13.0 | 3.3 | 390.3% | |
| Total wages/salary | Rs m | 16,408 | 3,937 | 416.8% | |
| Avg. sales/employee | Rs Th | 7,083.9 | 9,929.3 | 71.3% | |
| Avg. wages/employee | Rs Th | 1,265.4 | 1,185.1 | 106.8% | |
| Avg. net profit/employee | Rs Th | 855.1 | 1,207.7 | 70.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 91,857 | 32,985 | 278.5% | |
| Other income | Rs m | 374 | 1,170 | 31.9% | |
| Total revenues | Rs m | 92,230 | 34,155 | 270.0% | |
| Gross profit | Rs m | 20,367 | 5,245 | 388.3% | |
| Depreciation | Rs m | 2,644 | 162 | 1,632.9% | |
| Interest | Rs m | 2,373 | 38 | 6,212.6% | |
| Profit before tax | Rs m | 15,724 | 6,215 | 253.0% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -810 | 0 | - | |
| Tax | Rs m | 3,827 | 2,203 | 173.7% | |
| Profit after tax | Rs m | 11,088 | 4,012 | 276.4% | |
| Gross profit margin | % | 22.2 | 15.9 | 139.4% | |
| Effective tax rate | % | 24.3 | 35.4 | 68.7% | |
| Net profit margin | % | 12.1 | 12.2 | 99.2% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 68,746 | 22,655 | 303.5% | |
| Current liabilities | Rs m | 27,027 | 6,681 | 404.5% | |
| Net working cap to sales | % | 45.4 | 48.4 | 93.8% | |
| Current ratio | x | 2.5 | 3.4 | 75.0% | |
| Inventory Days | Days | 85 | 65 | 131.2% | |
| Debtors Days | Days | 96 | 29 | 327.7% | |
| Net fixed assets | Rs m | 24,132 | 835 | 2,888.5% | |
| Share capital | Rs m | 282 | 213 | 132.8% | |
| "Free" reserves | Rs m | 44,643 | 16,715 | 267.1% | |
| Net worth | Rs m | 44,925 | 16,928 | 265.4% | |
| Long term debt | Rs m | 45,363 | 0 | - | |
| Total assets | Rs m | 117,639 | 24,162 | 486.9% | |
| Interest coverage | x | 7.6 | 163.7 | 4.7% | |
| Debt to equity ratio | x | 1.0 | 0 | - | |
| Sales to assets ratio | x | 0.8 | 1.4 | 57.2% | |
| Return on assets | % | 11.4 | 16.8 | 68.3% | |
| Return on equity | % | 24.7 | 23.7 | 104.1% | |
| Return on capital | % | 19.1 | 36.9 | 51.8% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 56,152 | 369 | 15,236.2% | |
| Fx outflow | Rs m | 8,084 | 3,807 | 212.4% | |
| Net fx | Rs m | 48,068 | -3,438 | -1,398.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 6,574 | 1,527 | 430.5% | |
| From Investments | Rs m | -7,124 | -2,148 | 331.6% | |
| From Financial Activity | Rs m | 5,432 | -1,024 | -530.3% | |
| Net Cashflow | Rs m | 1,992 | -1,646 | -121.1% | |
Share Holding
| Indian Promoters | % | 48.3 | 0.0 | - | |
| Foreign collaborators | % | 0.0 | 75.0 | - | |
| Indian inst/Mut Fund | % | 6.9 | 7.9 | 87.3% | |
| FIIs | % | 34.4 | 0.1 | 34,400.0% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 10.5 | 17.1 | 61.4% | |
| Shareholders | 56,727 | 18,270 | 310.5% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare GLENMARK PHARMA With: NOVARTIS ASTRAZENECA PHARMA DISHMAN PHARMA IPCA LABS NATCO PHARMA
Compare GLENMARK PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)
Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.
Related Views on News
GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)
Aug 13, 2018 | Updated on Aug 13, 2018For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9% (Quarterly Result Update)
Jul 20, 2018 | Updated on Jul 20, 2018For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)
Aug 3, 2018In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.
The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)
Aug 3, 2018This price pattern can help you identify stocks on the verge of a turnaround.
Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)
Aug 3, 2018To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?
Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)
Aug 2, 2018Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.
Why HDFC Equity Fund Disappointed Its Investors(Outside View)
Aug 9, 2018Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.
More|
| |
GLENMARK PHARMA SHARE PRICE
Aug 14, 2018 (Close)
TRACK GLENMARK PHARMA
- Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GLENMARK PHARMA
GLENMARK PHARMA 5-YR ANALYSIS
COMPARE GLENMARK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.